These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
291 related articles for article (PubMed ID: 34561270)
61. Glioblastoma Immune Landscape and the Potential of New Immunotherapies. Daubon T; Hemadou A; Romero Garmendia I; Saleh M Front Immunol; 2020; 11():585616. PubMed ID: 33154756 [TBL] [Abstract][Full Text] [Related]
63. Targeted Therapies for the Treatment of Glioblastoma in Adults. Chuang DF; Lin X Curr Oncol Rep; 2019 May; 21(7):61. PubMed ID: 31102038 [TBL] [Abstract][Full Text] [Related]
64. Prospects of immune checkpoint modulators in the treatment of glioblastoma. Preusser M; Lim M; Hafler DA; Reardon DA; Sampson JH Nat Rev Neurol; 2015 Sep; 11(9):504-14. PubMed ID: 26260659 [TBL] [Abstract][Full Text] [Related]
65. Glioblastoma-derived mechanisms of systemic immunosuppression. Waziri A Neurosurg Clin N Am; 2010 Jan; 21(1):31-42. PubMed ID: 19944964 [TBL] [Abstract][Full Text] [Related]
66. Immunotherapy for Glioblastoma: Current Progress and Challenges. Yu MW; Quail DF Front Immunol; 2021; 12():676301. PubMed ID: 34054867 [TBL] [Abstract][Full Text] [Related]
67. The search for novel therapeutic strategies in the treatment of recurrent glioblastoma multiforme. Bambury RM; Morris PG Expert Rev Anticancer Ther; 2014 Aug; 14(8):955-64. PubMed ID: 24814143 [TBL] [Abstract][Full Text] [Related]
68. Using viral vectors to deliver local immunotherapy to glioblastoma. Haddad AF; Young JS; Aghi MK Neurosurg Focus; 2021 Feb; 50(2):E4. PubMed ID: 33524947 [TBL] [Abstract][Full Text] [Related]
69. Ipilimumab: an investigational immunotherapy for glioblastoma. Youssef G; Dietrich J Expert Opin Investig Drugs; 2020 Nov; 29(11):1187-1193. PubMed ID: 32945231 [TBL] [Abstract][Full Text] [Related]
70. Recent Development in NKT-Based Immunotherapy of Glioblastoma: From Bench to Bedside. Li Y; Sharma A; Maciaczyk J; Schmidt-Wolf IGH Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163235 [TBL] [Abstract][Full Text] [Related]
71. Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma. Goswami S; Walle T; Cornish AE; Basu S; Anandhan S; Fernandez I; Vence L; Blando J; Zhao H; Yadav SS; Ott M; Kong LY; Heimberger AB; de Groot J; Sepesi B; Overman M; Kopetz S; Allison JP; Pe'er D; Sharma P Nat Med; 2020 Jan; 26(1):39-46. PubMed ID: 31873309 [TBL] [Abstract][Full Text] [Related]
72. Immunotherapy for Glioblastoma: Adoptive T-cell Strategies. Choi BD; Maus MV; June CH; Sampson JH Clin Cancer Res; 2019 Apr; 25(7):2042-2048. PubMed ID: 30446589 [TBL] [Abstract][Full Text] [Related]
73. Recent advances and future challenges of tumor vaccination therapy for recurrent glioblastoma. Zhao B; Wu J; Li H; Wang Y; Wang Y; Xing H; Wang Y; Ma W Cell Commun Signal; 2023 Apr; 21(1):74. PubMed ID: 37046332 [TBL] [Abstract][Full Text] [Related]
74. The current and future aspects of glioblastoma: Immunotherapy a new hope? Patel V; Shah J Eur J Neurosci; 2021 Aug; 54(3):5120-5142. PubMed ID: 34107127 [TBL] [Abstract][Full Text] [Related]
75. Investigational treatment strategies in glioblastoma: progress made and barriers to success. Nelson TA; Dietrich J Expert Opin Investig Drugs; 2023; 32(10):921-930. PubMed ID: 37796104 [TBL] [Abstract][Full Text] [Related]
76. Emerging therapies for glioblastoma: current state and future directions. Rong L; Li N; Zhang Z J Exp Clin Cancer Res; 2022 Apr; 41(1):142. PubMed ID: 35428347 [TBL] [Abstract][Full Text] [Related]
78. The Dynamics of Interactions Among Immune and Glioblastoma Cells. Eder K; Kalman B Neuromolecular Med; 2015 Dec; 17(4):335-52. PubMed ID: 26224516 [TBL] [Abstract][Full Text] [Related]
80. Vaccination in the immunotherapy of glioblastoma. Kong Z; Wang Y; Ma W Hum Vaccin Immunother; 2018 Feb; 14(2):255-268. PubMed ID: 29087782 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]